Parkinson Disease
|
0.360 |
Biomarker
|
disease |
BEFREE |
These results demonstrate neuroinflammation, as well as negative regulation of neurotrophic factors (GDNF and NGF), may be involved in aminochrome-induced neurodegeneration, and they contribute to a better understanding of PD pathogenesis.
|
29588162 |
2018 |
Parkinson Disease
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
The aim of the present study was to investigate whether PACA could increase NGF levels against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) neurotoxicity in a mouse PD model.
|
28321769 |
2018 |
Parkinson Disease
|
0.360 |
Biomarker
|
disease |
BEFREE |
Synthetic peptides that can act as NGF receptor agonists (NGF mimetics) are known to attenuate neurodegenerative pathologies in experimental models of Alzheimer's disease and Parkinson's disease; however, the existence of plant-based NGF mimetics is uncertain.
|
29955238 |
2018 |
Parkinson Disease
|
0.360 |
Biomarker
|
disease |
BEFREE |
The glial cell line-derived neurotrophic factor (GDNF), one of the most potent useful neurotrophic factors for the treatment of Parkinson's disease (PD), is firstly synthesized as the proform (proGDNF) like other neurotrophin NGF, BDNF, and NT3.
|
23934644 |
2014 |
Parkinson Disease
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
Genetic studies have identified numerous factors linking β-adrenergic blockade to Parkinson's disease (PD), including human leukocyte antigen genes, the renin-angiotensin system, poly(adenosine diphosphate-ribose) polymerase 1, nerve growth factor, vascular endothelial growth factor, and the reduced form of nicotinamide adenine dinucleotide phosphate.
|
23695225 |
2013 |
Parkinson Disease
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
IGF-I and IGF-II resistance was present in DLB but not PD frontal cortex, and associated with reduced expression of Hu, nerve growth factor, and Trk neurotrophin receptors, and increased levels of glial fibrillary acidic protein, alpha-synuclein, dopamine-beta-hydroxylase, 4-hydroxy-2-nonenal (HNE), and ubiquitin immunoreactivity.
|
19276553 |
2009 |
Parkinson Disease
|
0.360 |
Biomarker
|
disease |
CTD_human |
IGF-I and IGF-II resistance was present in DLB but not PD frontal cortex, and associated with reduced expression of Hu, nerve growth factor, and Trk neurotrophin receptors, and increased levels of glial fibrillary acidic protein, alpha-synuclein, dopamine-beta-hydroxylase, 4-hydroxy-2-nonenal (HNE), and ubiquitin immunoreactivity.
|
19276553 |
2009 |